Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase
Timothy L. Frankel(University of Michigan), Richard A. Morgan(Sarepta Therapeutics (United States))
Cited by 82
Related Papers
High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines
|The Journal of Immunology|2007|216
Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry
|Journal of Translational Medicine|2012|143
A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions
|International Journal of Molecular Sciences|2024|13